GlassScriptPhysician profile
Damali N Muwonge
NPI 1710684212
$7,805.14
in general payments reported to CMS, 2019-2025
27 companies · $3,169 in 2025
The $3,169 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,111 · 2024: $2,526 · 2025: $3,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,522 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,521.96 |
| Education | $283.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $968.24 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $796.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $681.93 | 2023-2025 | Tezspire, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $647.24 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $537.73 | 2023-2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $487.92 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $434.98 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.67 | 2023-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $387.30 | 2023-2025 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $312.64 | 2023-2025 | Quviviq, Quviviq |
| Insmed, INC. | $308.54 | 2023-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $283.37 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Corium, LLC | $279.09 | 2023-2025 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $233.84 | 2023-2025 | Dupixent |
| Amgen INC. | $189.12 | 2024-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $155.28 | 2023-2024 | Yupelri |
| Genzyme Corporation | $133.10 | 2024-2025 | |
| Inspire Medical Systems, INC. | $127.92 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Viatris Specialty LLC | $86.19 | 2025 | Yupelri |
| Lilly USA, LLC | $69.73 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $54.74 | 2023-2025 | Acthar |
| 3b Medical, INC. | $49.51 | 2025 | Luna |
| United Therapeutics Corporation | $28.09 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $26.52 | 2023 | Belsomra |
| Tris Pharma INC | $18.98 | 2023 | Dyanavel Xr |
| Azurity Pharmaceuticals, INC. | $16.17 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damali Muwonge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.